CurveBeam AI opens China market after HiRise clearance and record Q1 orders

China clearance opens the next HiRise sales phase

CurveBeam AI Limited (ASX:CVB) has cleared a key regulatory barrier in China, with its HiRise weight-bearing CT system receiving National Medical Products Administration approval on 12 October. The clearance triggers a A$1.0 million payment from partner Weiying and is expected to support Weiying and WEGO Orthopaedics’ initial order of U.S.-manufactured systems for distribution in China.

The company says a further A$3.0 million in milestone payments is linked to Chinese sales: A$1.0 million when the first 10 systems are sold and A$2.0 million after the first 50. Those payments would sit alongside product revenue, but the filing does not provide a timing estimate for the initial order or the later milestones. Launch preparations have included key opinion leader outreach, potential reference-site selection and training on manufacturing, assembly and service processes.

The China push has already been backed by a recent funding program. CurveBeam’s A$1.75 million shortfall raise was reported in September as part of capital earmarked for the HiRise launch, development, supply-chain preparation and working capital.

Five HiRise orders set a Q1 record

CurveBeam secured purchase orders for five HiRise devices during the three months to 30 September, with two orders in the United States and three in Europe. It called the result its strongest first-quarter sales performance to date. The company carried A$4.9 million of purchase orders and receivables into the December quarter, up from A$4.2 million entering Q1.

That sales measure is more encouraging than the cash-receipts line. Customer receipts were A$1.80 million, down 30% from A$2.58 million in the previous quarter but 31% above the comparable quarter’s A$1.37 million. CurveBeam says its normal revenue cycle runs from two to six months between an order, installation and full payment, meaning the carried-forward balance will need to convert into cash before the commercial progress becomes visible in reported receipts.

FDA clearance extends the product pipeline

In the United States, CurveBeam received FDA 510(k) clearance during September for its CT-based Bone Mineral Density technology on multidetector CT scans. The approval is for the company’s first MDCT BMD product, while further work remains to complete automated region-of-interest selection and the reporting of T and Z scores.

CurveBeam plans to use the clearance as the foundation for a separate Special 510(k) submission that would extend the BMD capability to HiRise. The company has begun scoping and budgeting targeted data collection for that submission. This is a staged regulatory pathway rather than clearance of the HiRise BMD application itself, a distinction also present in the company’s earlier MDCT BMD FDA clearance.

Funding buys time for commercial execution

CurveBeam raised A$7.35 million through a A$5.0 million placement at A$0.02 a share, a A$0.6 million share purchase plan at A$0.018 and a further A$1.75 million through a shortfall offer and placement. Operating cash use fell 44% to A$1.36 million from A$2.42 million in Q4 FY26 after staff and other operating-cost reductions, which brought annualised cash-related operating expenditure to about A$15 million.

The quarter ended with A$5.83 million in cash and an estimated 4.3 quarters of funding based on the quarter’s operating cash use. The 4C also records A$1.77 million of government grants and tax incentives in operating cash inflows, while financing cash flow included A$7.14 million of equity proceeds, A$1.25 million of borrowings repaid and A$143,000 of lease payments. The runway calculation therefore provides a snapshot based on the reported quarter, not a guarantee that funding needs will remain unchanged.

Robotic surgery validation remains unfinished

Separately, HiRise scans processed successfully through software workflows used with a major robotic-assisted surgery platform, with motion failure rates below the company’s stated acceptable thresholds. Formal validation for total knee replacement is progressing, while similar trials for total hip replacement are planned subject to regulatory and clinical governance requirements. CurveBeam is also pursuing collaborations with other robotic surgery platforms.

The immediate test for the quarter’s positive regulatory and sales news is conversion: whether China clearance produces the expected Weiying order, whether the A$4.9 million carried-forward balance turns into receipts, and whether cost reductions can hold while the company advances additional regulatory work.